Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Accelrys Announces Fiscal Second Quarter 2008 Financial Results

Abstract:
Delivers Increased Profitability in Q208

Accelrys Announces Fiscal Second Quarter 2008 Financial Results

San Diego, CA | Posted on November 1st, 2007

Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for its fiscal second quarter ended September 30, 2007.

This quarter included several financial and operational achievements for Accelrys, said Mark Emkjer, Accelrys President and Chief Executive Officer. We had another successful financial quarter, again showing increased profitability on a year over year basis. We also continued to leverage our scientific operating platform to develop scientific business intelligence solutions aimed at serving our markets. In addition, we completed the modernization of our life science modeling and simulations product line with the launch of Discovery Studio 2.0, which has been very well received and expands our scientific leadership role in the marketplace. Finally, we entered into a strategic relationship with Agilent Technologies, significantly expanding our distribution network to several new markets. We believe these achievements will provide growth opportunities in the coming quarters.

Financial Results:

Revenue for the quarter ended September 30, 2007 was $19.7 million, compared to revenue of $20.2 million for the same quarter of the previous year. Revenue in the current quarter was impacted by reduced revenues from de-emphasized products, partially offset by continued growth in the solutions and services surrounding the Companys scientific operating platform product line.

Non-GAAP operating income was $2.6 million for the current quarter, which was slightly higher than non-GAAP operating income for the same quarter of the previous year. On a GAAP basis, operating income for the current quarter was $1.3 million, a 49% increase over GAAP operating income of $0.8 million for the same quarter of the previous year. Operating income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by savings realized in connection with cost control measures implemented in previous periods, partially offset by increased personnel related costs associated with our expanded sales organization.

Non-GAAP net income was $3.0 million, or $0.11 per diluted share, for the current quarter, a 13% increase from non-GAAP net income of $2.6 million, or $0.10 per diluted share, for the same quarter of the previous year. On a GAAP basis, the Company reported net income of $1.6 million, or $0.06 per diluted share, for the current quarter, a 75% increase from GAAP net income of $0.9 million, or $0.04 per diluted share, for the same quarter of the previous year. Net income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by both the savings realized in operating income noted above and increased interest income due to higher interest rates and cash balances in this quarter versus the second quarter of the prior year.

At September 30, 2007, the Company had total cash, cash equivalents, restricted cash and marketable securities of $64.9 million, an increase of $3.7 million from the same quarter of the previous year.

Recent Financial, Business and Product Development Highlights:

Entered into a comprehensive bilateral resale agreement with Agilent Technologies Inc., enabling the mutual distribution and integration of each companys informatics products, as well as Agilents distribution of our scientific operating platform. The partnership covers the breadth of informatics portfolios of both companies and will enable customers in the pharmaceutical and industrial chemicals industries to enjoy unprecedented integration of laboratory data, experimental results and insights across the enterprise.

Released Discovery Studio 2.0, which includes new and enhanced life science modeling and simulation functionality, in a modernized, easy to use interface which leverages our scientific operating platform to enable simplification of complex workflows.

Released Material Studio 4.2 which provides scripting enhancements, new Materials Visualizer tools and innovative workflow capabilities for automating and customizing modeling and simulation tasks in the areas of catalysis, crystallization, polymers and visualization.

Launched Phase 2 of the nanotech consortium which continues the collaborative development from Phase 1 and focuses on developing tools and protocols that bridge the gap between atomistic simulations and engineering applications.

Appointed Jeffrey Rodek, Former Executive Chairman of the Board of Directors of Hyperion Solutions Corporation, to its Board of Directors.

Appointed Rohit Shyam as Vice President of Corporate Development and Strategy. Mr. Shyam joins the Company from Computer Sciences Corporation where he served as Partner, Senior Strategy Expert, and Solution Director. Mr. Shyam will focus full time on corporate development, mergers and acquisitions and strategy.

Non-GAAP Financial Measures:

This press release describes financial measures for operating income, net income, and net income per share that exclude stock-based compensation expense, amortization of purchased intangible assets, restructuring charges and costs incurred in the prior year to complete the Companys restatement. These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles.

Management believes these non-GAAP financial measures provide a useful measure of the Companys operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Companys ongoing operating performance. Further, management and the Board of Directors utilize these measures, in addition to GAAP measures, when evaluating and comparing the Companys operating performance against internal financial forecasts and budgets. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

For additional information on the items excluded by the Company from its non-GAAP financial measures please refer to the Form 8-K regarding this release that was furnished today to the Securities and Exchange Commission.

The following table contains a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures (unaudited, amounts in thousands, including footnotes):

  Three Months Ended

September 30,

  Six Months Ended

September 30,

2007   2006 2007   2006
 
GAAP Operating income $ 1,256 $ 844 $ 2,086 $ 428
Stock-based compensation expense1 965 1,327 1,868 2,336
Purchased intangible asset amortization2 381 384 762 768
Restructuring charges3 25
Restatement-related costs3         493
Non-GAAP Operating income $ 2,602 $ 2,555 $ 4,741 $ 4,025
GAAP Net income $ 1,640 $ 935 $ 3,059 $ 606
Stock-based compensation expense 965 1,327 1,868 2,336
Purchased intangible asset amortization 381 384 762 768
Restructuring charges3 25
Restatement-related costs3         493
Non-GAAP Net income $ 2,986 $ 2,646 $ 5,714 $ 4,203
GAAP Basic and diluted net income per share $ 0.06 $ 0.04 $ 0.11 $ 0.02
Stock-based compensation expense 0.04 0.05 0.07 0.09
Purchased intangible asset amortization 0.01 0.01 0.03 0.03
Restructuring charges3
Restatement-related costs3         0.02
Non-GAAP Basic and diluted net income per share $ 0.11 $ 0.10 $ 0.21 $ 0.16

1 Stock-based compensation expense is included in our condensed consolidated statement of operations as follows:

 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

2007   2006 2007   2006
 
Cost of revenue $ 83 $ 83 $ 164 $ 154
Product development 227 393 457 738
Sales and marketing 250 221 451 380
General and administrative   405   630   796   1,064
Total stock-based compensation expense $ 965 $ 1,327 $ 1,868 $ 2,336

2 Purchased intangible asset amortization is included in the cost of revenue line in our condensed consolidated statement of operations.

3 Restructuring charges and restatement-related costs are included in the general and administrative expenses line in our condensed consolidated statement of operations.

Conference Call Details:

At 5:00 p.m. ET today, Accelrys will conduct a conference call to discuss its financial results. To participate, please dial (866) 831-6243 (+(617) 213-8855 outside the United States) and enter the access code, 15005142, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live on the Investor Relations section of the Accelrys website at www.accelrys.com.

A replay of the conference call will be available online at www.accelrys.com and via telephone by dialing (888) 286-8010 (+1 (617) 801-6888 outside the United States) and entering access code, 64106248, beginning 7:00 p.m. ET on November 1, 2007 through 5:00 p.m. ET on February 1, 2008.

ACCELRYS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 
 

Three Months Ended
September 30,

 

Six Months Ended
September 30,

2007   2006 2007   2006
 
Revenue $ 19,663 $ 20,232 $ 39,764 $ 40,382
Cost of revenue   3,445   3,537   6,952   7,193
Gross margin 16,218 16,695 32,812 33,189
Operating expenses:
Product development 4,296 4,916 8,605 10,042
Sales and marketing 7,141 6,568 14,681 13,634
General and administrative   3,525   4,367   7,440   9,085
Total operating expenses   14,962   15,851   30,726   32,761
Operating income 1,256 844 2,086 428
Interest and other income, net   701   360   1,693   844
Income before taxes 1,957 1,204 3,779 1,272
Income tax expense   317   269   720   666
Net income $ 1,640 $ 935 $ 3,059 $ 606
Basic and diluted net income per share $ 0.06 $ 0.04 $ 0.11 $ 0.02
Weighted average shares used to compute basic and diluted net income per share
Basic 26,684 26,293 26,623 26,252
Diluted 27,076 26,420 26,985 26,387

ACCELRYS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 
 

September 30,
2007

 

March 31,
2007

Assets
Cash and marketable securities1 $ 64,887 $ 70,757
Trade receivables, net 10,011 18,617
Other assets, net2   58,691   65,227
Total assets $ 133,589 $ 154,601
Liabilities and stockholders equity
Current liabilities, excluding deferred revenue 11,605 21,136
Total deferred revenue3 38,800 56,133
Noncurrent liabilities, excluding deferred revenue 8,290 8,342
Total stockholders equity   74,894   68,990
Total liabilities and stockholders equity $ 133,589 $ 154,601

1 Cash, cash equivalents, and marketable securities consist of the following line items in our condensed consolidated balance sheet: Cash and cash equivalents; Marketable securities; and Restricted cash and marketable securities

2 Other assets, net, consists of the following line items in our condensed consolidated balance sheet: Prepaid expenses, deferred tax assets and other current assets; Property and equipment, net; Goodwill; Purchased intangible assets, net; Other assets

3 Total deferred revenue consists of the following line items in our condensed consolidated balance sheet: Current portion of deferred revenue; and Deferred revenue, net of current portion

####

About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design and drug discovery and development. Our technology and services are designed to meet the needs of today’s leading research and development organizations including leading commercial, government and academic organizations. Many of the largest pharmaceutical, biotechnology, chemical, and petroleum companies worldwide use our solutions. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/ .

Forward-Looking Statements:

Statements contained in this press release relating to the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. Such forward-looking statements including, but not limited to, statements relating to the impact of the Company’s relationship with Agilent Technologies and the growth of the Company, are subject to a number of risks and uncertainties. These include risks that the Company will not achieve its anticipated results or growth plans, that the Company’s competitive position will not improve, and/or that such growth will not occur due to, among other possibilities, a lack of demand for or market acceptance of the Company’s products, as well as the risks and uncertainties that are contained from time to time in the Company’s SEC filings, including, but not limited to, the Company’s Annual Report on Form 10-K for the year ended March 31, 2007, quarterly reports on Form 10-Q and current reports on Form 8-K. The Company’s actual results could differ materially from those projected in such forward-looking statements due to these risks and uncertainties, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.

For more information, please click here

Contacts:
Accelrys, Inc.
Rick Russo, 858-799-5200
or
Investor Relations:
MKR Group
Charles Messman or Todd Kehrli, 323-468-2300

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Wyatt Technology’s 24th International Light Scattering Colloquium to Highlight Developments in Applications and Characterization of Nanoparticles August 21st, 2014

Ultra-short pulse lasers & Positioning August 21st, 2014

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Financial Reports

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Harris & Harris Group Reports Financial Statements as of June 30, 2014 August 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE